Mereo BioPharma Group plc (MREO) experienced an increase of 6.42% in the aftermarket. However, the last trading session closed at $2.18 with a decrease of 3.11%.
Completion of the IMPACT Survey enrollment
On 13th October 2021, MREO announced enrolment in the biggest worldwide data collection regarding the effect of OI on individuals with Osteogenesis Imperfecta (OI). The IMPACT Survey received approximately 2200 individual answers from 65 countries over the course of three months. The survey results will assist future joint efforts aimed at improving OI diagnosis, treatment, and care. It will also prompt assessment and availability of possible novel therapies.
The findings of a comprehensive literature review conducted by MREO were presented at the American Society for Bone. MREO, Ultragenyx (partners in the development of setrusumab for the treatment of OI), and the OI community, coordinated by the umbrella organizations OIFE and OIF, collaborated closely to make the IMPACT Survey a reality.
Phase 2b ASTEROID Study of UX143 Data by MREO
MREO and Ultragenyx Presented Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta on 1st October 2021. Studies in the Phase 2b ASTEROID trial previously revealed that a daily dosage has a meaningful bone-building impact in elderly patients. This impact was assessed by comparing areal bone mineral density (BMD) at the lumbar spine to baseline. Moreover, treatment with UX143 resulted in a dose-dependent rise in P1NP serum levels.
In addition, UX143 is a completely human monoclonal antibody that inhibits sclerostin. It is a protein that suppresses the activity of bone-forming cells by acting on a critical bone-signaling route. Moreover, the objective of inhibiting sclerostin’s inhibitory actions is to promote new bone formation, collagen synthesis, and bone mineral density and strength. Lastly, Sclerostin inhibition also lowers excessive bone resorption, improving bone density even further.
Appointment of Pierre Jacquet to Board of Directors
MREO announced the appointment of Pierre Jacquet to the board of directors on 20th September 2021. Dr. Jacquet is Vice Chairman and Managing Director of L.E.K. Consulting’s Healthcare practice. Moreover, he has held a number of leadership positions, including Global Head, Healthcare Practice, and Global Leadership Team. Dr. Jacquet studied as a surgical resident at the University of Liège in Belgium and served as a Fellow at the Washington Cancer Institute.
